Clinical Trial

Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Since patients with spinal metastases are living longer, durable palliation with long-term tumor control are becoming increasingly important. EBRT results in durable local control of bone metastasis. However, about 25 % of patients with spinal metastases only achieved complete pain relief following EBRT for a median duration of less than 4 months. This could be partly due to spinal instability. In addition, almost half of the patients who receive EBRT will subsequently develop VCFs . Hence, RT does not stabilize the spine secondary to VCFs and is not effective in preventing imminent VCFs. Vertebroplasty has rapidly reduced pain and improved function in patients with VCFs. However, vertebroplasty does not provide local tumor control similar to EBRT. It is theorized that combining vertebroplasty with EBRT will stabilize the spine, relieve the pain, prevent imminent VCFs and minimize or avoid the need for opioids. It is hypothesized that combining a spine stabilization procedure such as vertebroplasty with RT will be the most effective management for patients with spinal metastases than RT alone for patients with spinal metastases. Combined vertebroplasty and radiotherapy is not a standard treatment option at present. This study is designed to quantify the advantage of adding vertebroplasty to radiotherapy for patients with spinal metastases. If the study is proven to be significant, it could become the standard of care for patients with spinal metastases.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-01-23; most recent amendment 2025-06-24.
Status change: Not Yet Recruiting → Recruiting 2024-06-11
Trial Details
NCT Number NCT04242589
Lead Sponsor AHS Cancer Control Alberta
Collaborators: Cross Cancer Institute
Conditions Spinal Metastases
Enrollment 64 participants
Start Date 2021-03-03
Primary Completion 2025-09-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-26